Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX +2.99%56 Cyclically Adjusted PB Ratio is 15.93 as of Jul. 15, 2026, which is 28% above its 10-year median of 12.40. GuruFocus rates AMRX with a GF Scoreâ„¢ of 56/100 and a GF Valueâ„¢ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 759 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 95.52% on this metric.
The historical rank and industry rank for Amneal Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
AMRX'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 10.95 Med: 12.4 Max: 15.53
Current: 15.53
During the past 10 years, Amneal Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 15.53. The lowest was 10.95. And the median was 12.40.
AMRX's Cyclically Adjusted PB Ratio is ranked worse than 95.52% of 759
companies
in the Drug Manufacturers industry
Industry Median: 1.82
vs AMRX: 15.53
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Amneal Pharmaceuticals's adjusted book value per share data of for the fiscal year that ended in Dec25 was $-0.225. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.08 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Amneal Pharmaceuticals (NAS:AMRX) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Amneal Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms
Amneal Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Amneal Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals Cyclically Adjusted PB Ratio Chart
AMRX vs INDV, KNSA, LQDA: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Amneal Pharmaceuticals Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 15.93 mean?
Amneal Pharmaceuticals (AMRX) has a Cyclically Adjusted PB Ratio of 15.93 as of Jul. 15, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Amneal Pharmaceuticals and its competitors. This is 28% above median its historical median of 12.40. Over the past decade, Amneal Pharmaceuticals' Cyclically Adjusted PB Ratio has ranged from 10.95 to 15.53. According to the industry distribution chart, Amneal Pharmaceuticals ranks #725 out of 759 companies in the Drug Manufacturers industry, placing it in the top 95.5%.
Is Amneal Pharmaceuticals' Cyclically Adjusted PB Ratio too high?
Amneal Pharmaceuticals' current Cyclically Adjusted PB Ratio of 15.93 is 28% above median its 10-year median of 12.40. Over the past 10 years, this metric has ranged from a low of 10.95 to a high of 15.53. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.82. Amneal Pharmaceuticals' value of 15.93 is 775.3% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #725 out of 759 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amneal Pharmaceuticals has a GF Scoreâ„¢ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Cyclically Adjusted PB Ratio compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #725 out of 759 companies for Cyclically Adjusted PB Ratio. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.82. Amneal Pharmaceuticals' value of 15.93 is 775.3% above this benchmark. Historically, Amneal Pharmaceuticals' own Cyclically Adjusted PB Ratio has ranged from 10.95 to 15.53 over the past decade. While the company's 10-year median is 12.40 vs. the industry median of 1.82, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.82, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current Cyclically Adjusted PB Ratio of 15.93 is 775.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current Cyclically Adjusted PB Ratio is 15.93, which is 28% above median its own 10-year median of 12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $17.20 — trading 126.9% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 15.93, which is 28% above median its 10-year median of 12.40 and 775.3% above the Drug Manufacturers industry median of 1.82. Amneal Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Cyclically Adjusted PB Ratio is 15.93 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.20 is trading 126.9% above its estimated GF Value™ of $7.58.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
Cyclically Adjusted PB Ratio: 15.93 (28% above median its 10-year median of 12.40)
GF Value™: $7.58 vs. price of $17.20 (126.9% above fair value)
Industry Position: 775.3% above the Drug Manufacturers median (#725 of 759)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score
Get the complete analysis for AMRX
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
